Suspension of trading

MYND Life Sciences Inc.

MYND

CA62857B1094

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 10:07:02 2025-04-22 am EDT			5-day change	1st Jan Change
0.0700 ^CAD	-.--%		-.--%	-30.00%

Nov. 10	Alert inadvertently tagged to Mynd Life Sciences withdrawn	RE
Jan. 10	MYND Life Sciences Inc. Announces Colin Campbel Stepping Down as Chief Executive Officer	CI

Alert inadvertently tagged to Mynd Life Sciences withdrawn

Published on 11/10/2025 at 08:55 am EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about MYND Life Sciences Inc.

Nov. 10	Alert inadvertently tagged to Mynd Life Sciences withdrawn	RE
Jan. 10	MYND Life Sciences Inc. Announces Colin Campbel Stepping Down as Chief Executive Officer	CI
Nov. 22	MYND Life Sciences Inc. Appoints Lana Hoogenboom to Its Board of Directors	CI
24-10-01	MYND Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2024	CI
24-07-02	MYND Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	CI
24-03-20	MYND Life Sciences Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	CI
24-03-04	MYND Life Sciences Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	CI
24-03-03	MYND Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	CI
24-01-30	MYND Life Sciences Inc. Appoints Laurie Bakke as an Independent Non-Executive Director	CI
23-12-06	Mynd Announces Transition of Dr. Lyle Oberg, E.C.A. to Executive Chairman from the Role of CEO	CI
23-12-06	Mynd Announces Transition of Dr. Lyle Oberg, E.C.A. from the Role of CEO to Executive Chairman	CI
23-12-06	MYND Life Sciences Inc. Appoints Mr. John Campbell as Chief Executive Officer	CI
23-12-06	MYND Life Sciences Inc. Appoints John Campbell as President	CI
23-10-24	MYND Life Sciences Inc. entered into a non-binding letter of intent to acquire Cava Healthcare Inc.	CI
23-09-19	MYND Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	CI
23-06-28	MYND Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	CI
23-05-05	MYND Life Sciences Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	CI
23-04-27	MYND Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	CI
23-04-27	MYND Life Sciences Inc. Reports Earnings Results for the Full Year Ended October 31, 2022	CI
22-09-27	MYND Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	CI
22-06-28	VMYND Lifesciencs Inc. cancelled the acquisition of Tidal Psychedelics.	CI
22-06-23	MYND Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2022	CI
22-06-01	MYND Life Sciences Inc. Announces New Testing Methodologies for Measuring Cellular Responses to Microdosing with Psilocybins	CI
22-04-20	MYND Lifesciencs Inc. announced that it expects to receive CAD 3.5 million in funding	CI
22-03-31	MYND Lifesciencs Inc. Reports Earnings Results for the First Quarter Ended January 31, 2022	CI

MYND Life Sciences Inc. is a Canada-based life science based, neuro-pharmaceutical drug development company. The Company is working on advancing medicines based on neuro-anti-inflammatory substances through rigorous science and clinical trials, with an initial focus on major depressive disorder (MDD). Its lead development program, referred to as the human mycogene modulation program (HMM), is designed to treat neuropsychiatric disorders through the dosing of formulations of psilocybin and/or its analogs. It is evaluating additional indications for its HMM program, including autoimmune disorders (AD) and other MDD conditions as well as multiple sclerosis, and Alzheimerâs disease. Its programs include MYND-604 and MYND-778.

Employees

Sector

Biotechnology & Medical Research

More about the company